Completed

Based on the Theory of Gut-brain Axis, the Intervention Effect and Related Mechanism of Ganoderma Lucidum Spore Powder on Depressive Symptoms in Patients With Thyroid Cancer Were Investigated

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Ganoderma lucidum spore powder

+ placebo

Dietary SupplementOther
Who is being recruted

Behavior+7

+ Behavioral Symptoms

+ Depression

From 18 to 80 Years
+13 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-Controlled
Interventional
Study Start: March 2023
See protocol details

Summary

Principal SponsorLing Zhiqiang
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: March 28, 2023

Actual date on which the first participant was enrolled.

This study is exploring how a natural supplement called Ganoderma lucidum spore powder might help reduce depressive symptoms in patients with thyroid cancer. The focus is on the gut-brain axis theory, which suggests that the health of the gut can affect mental health. This research is significant because it could offer a new way to improve the mental well-being of thyroid cancer patients, a group that can experience significant emotional challenges during their treatment and recovery. Participants in the study are randomly divided into two groups. Two-thirds receive the Ganoderma lucidum spore powder, and one-third receive a placebo, both taken orally at a dose of 4 grams per day over a period of 90 days. This study is conducted in a double-blind manner, meaning neither the participants nor the researchers know who receives the actual supplement or the placebo. The outcomes of the study will focus on the effects of the Ganoderma lucidum spore powder on depressive symptoms, aiming to determine its effectiveness in improving patients' mental health.

Official TitleBased on the Theory of Gut-brain Axis, the Intervention Effect and Related Mechanism of Ganoderma Lucidum Spore Powder on Depressive Symptoms in Patients With Thyroid Cancer Were Investigated
NCT06429514
Principal SponsorLing Zhiqiang
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

298 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Female

Biological sex of participants that are eligible to enroll.

From 18 to 80 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

BehaviorBehavioral SymptomsDepressionEndocrine System DiseasesEndocrine Gland NeoplasmsHead and Neck NeoplasmsNeoplasmsNeoplasms by SiteThyroid DiseasesThyroid Neoplasms

Criteria

6 inclusion criteria required to participate
patients with depressive symptoms after surgery for papillary thyroid carcinoma in the outpatient department of Zhejiang Cancer Hospital
Han nationality
No previous depression and other mental diseases
18-80 years old
Show More Criteria
7 exclusion criteria prevent from participating
suffering from other diseases of the intestinal system
Gastrointestinal surgery was performed before intervention
Including patients with other malignant tumors, who need chemotherapy, radiotherapy, biological therapy or traditional Chinese medicine treatment received antibiotics or microecological modulators within 3 months before the intervention
Acute intestinal obstruction
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
Oral administration of Ganoderma lucidum spore powder 4g per day ( 1 bag at a time, 2 times a day, 2g / bag ) for 90 days

Group II

Placebo
Oral ' placebo ' 4g per day ( 1 bag at a time, 2 times a day, 2g / bag ) for 90 days.

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Zhejiang Cancer Hospital

Hangzhou, ChinaOpen Zhejiang Cancer Hospital in Google Maps
CompletedOne Study Center